The value of a German life science company hinges on its patent portfolio, particularly for targeting the major markets of US and Europe. Differences in legal requirements between the US and Europe can be critical. Acceptable patent practice in Europe can be fatal in the US, and vice versa. The legal requirements in the US and Europe continue to evolve, bringing new opportunities and pitfalls. Dealmakers must be aware of the key issues affecting the development and valuation of a patent portfolio. Panelists will discuss and contrast the key issues relevant for German life science companies.
Continuation and divisional practice in US and Europe
Claiming methods of treatment in Europe
Filing decisions given available test data
US pitfalls: Best mode requirement and inequitable conduct
Filing PCT applications in English to accelerate US prior art status
US Patent Term Adjustment post-Wyeth
Impact of Biosimilar legislation as part of U.S. Health Care Reform
Implications of Bilski, Prometheus and Myriad decisions and comparison with the current law in Europe
Speakers:
Dr. Rouget F. (“Ric”) Henschel (U.S. Patent Attorney, member of Virginia and District of Columbia Bars), Foley & Lardner
Dr. Fritz Lahrtz (German and European Patent and Trademark Attorney), Isenbruck
Related Insights
July 25, 2025
Foley Viewpoints
Thorny Laws That ICHRA Vendors Should Consider, Part Three: FinTech Edition
We continue our series on the legal and regulatory challenges facing individual coverage health reimbursement arrangements (ICHRAs); this…
July 24, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
July 23, 2025
Foley Viewpoints
The One Big Beautiful Bill and Workplace Immigration Enforcement
The “One Big Beautiful Bill Act,” signed into law by President Trump on July 4, 2025, will fund government efforts to continue to…